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ABSTRACT
Immunotherapy with PD-1/PD-L1-blocking antibodies is clinically effective for several tumor types,
but the mechanism is not fully understood. PD-L1 expression on tumor biopsies is generally
regarded as an inclusion criterion for this cancer therapy. Here, we describe the PD-L1-blocking
therapeutic responses of preclinical tumors in which PD-L1 expression was removed from cancer
cells, but not from immune infiltrate. Lack of PD-L1 expression on malignant cells delayed tumor
outgrowth in a CD8C T cell-mediated fashion, showing the importance of this molecule in immune
suppression. PD-L1 expression was evident on myeloid-infiltrating cells in the microenvironment of
these tumors and targeting stromal PD-L1 with blocking antibody therapy had additional antitumor
effect, demonstrating that PD-L1 on both malignant cells and immune cells is involved in the
mechanism of immunotherapeutic antibodies. Importantly, comparable results were obtained with







The co-inhibitory receptor PD-1 and its ligand PD-L1 form a
well-known immune-inhibiting axis, and engagement of PD-
1 on T cells is important for maintaining peripheral toler-
ance and preventing over-activation of the immune system.
PD-L1 expression by tumors is a powerful escape mechanism
through which tumors can evade control by T cell immu-
nity.1,2 The clinical relevance of this immunosuppressive
pathway was emphasized by the clinical successes of PD-1
and PD-L1 checkpoint blockade therapies in a range of solid
tumors.3–6 Beneficial outcome of PD-1 and PD-L1 therapy
has been correlated with mutational burden of the cancer
cells, presence of tumor-infiltrating T cells and PD-L1
expression.1,2,7,8 Tumor cells may upregulate PD-L1 to coun-
teract immune attack in response to soluble mediators of T
cell responses, including interferons and interleukins.1,2
However, various types of cancer constitutively express PD-
L1, either as a result of structural alterations in the regula-
tory 30 region of the PD-L1 gene,9 or through activation of
the STAT3 and AKT pathways, which are common features
of cancer.10,11 Although several studies have investigated
PD-1 and PD-L1 interactions within tumors, the exact cellu-
lar mechanisms are not completely elucidated.1,2 PD-L1 can
be expressed by malignant cells, but is also expressed on
infiltrating cells within tumors, such as macrophages,
neutrophils, endothelial cells and fibroblasts. Currently, arbi-
trary cut-off values for the percentage of overall PD-L1 stain-
ing in the total tumor area are used to classify tumor
biopsies as positive or negative for PD-L1 expression. A
recent study described a correlation between PD-L1 expres-
sion and an improved response to PD-L1 blockade in a clini-
cal trial of multiple types of cancer patients, especially when
expression was on tumor-infiltrating cells.12 However, no
convincing proof of the relative importance of tumor-
expressed versus stromal-expressed PD-L1 to therapy
response exists to date. For future use as a predictive bio-
marker for therapeutic responsiveness, it is essential to
understand the relevance of the expression pattern of PD-L1
within the tumor area. To evaluate this topic, we made use
of two mouse tumor models (MC38 and CT26) on two dif-
ferent genetic backgrounds in which the PD-L1 gene in the
cancer cells was knocked out with CRISPR-Cas9 technology.
We show here that PD-L1 expressed on cancerous cells is
not exclusively responsible for the therapeutic effect of PD-
1/PD-L1 checkpoint blockade and that PD-L1 on infiltrating
(mostly myeloid) cells contributes significantly. Our data
indicate that PD-L1 expression on malignant cells is not
required for successful PD-1/PD-L1-blocking therapy, which
has important clinical implications regarding patient inclu-
sion strategies for immune checkpoint blockade.
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Results and discussion
PD-L1 is expressed on tumor cells and immune-infiltrating
cells
PD-L1 expression was determined in MC38 and CT26 tumors,
two widely used murine colon carcinoma models that are
responsive to several types of immunotherapy including PD-L1
blockade, and are known to have a high mutational load leading
to neo-antigen presentation.13,14 After staining sections of
excised MC38 and CT26 tumors with PD-L1 antibody, we
observed heterogeneous PD-L1 expression throughout the
tumor, with faint expression on some cells and strong expression
on clusters of other cells (Fig. 1A). Several correlation studies
have been done on PD-L1 expression and prognosis, however,
many are fraught with practical problems including heteroge-
neous expression patterns and antibody variability. 15–17 Unlike
the majority of clinical PD-L1 biomarker assays, one assay dis-
tinguishes expression on malignant cells versus tumor-infiltrat-
ing immune cells.12 To dissect the role of PD-L1 expression on
tumor versus non-tumor cells, we created PD-L1-deficient var-
iants of MC38 and CT26 tumor cells using CRISPR-Cas9
technology. Complete PD-L1 knockdown was confirmed by
flow cytometry after interferon-gamma (IFNg) stimulation in
vitro (Fig. 1B). In order to specify which cells in MC38 and
CT26 tumors express PD-L1, we inoculated mice with WT and
PD-L1KO tumor cells and analyzed the cell suspensions of
excised tumors by flow cytometry. We determined that in WT
tumors, PD-L1 expression was present on CD45-negative tumor
cells, but also strongly on CD45C immune infiltrate (Fig. 1C).
PD-L1KO tumors still contained this strong PD-L1 expression on
CD45C immune cells (Fig. 1D). A recent study in other mouse
tumor models reported that PD-L1 deficiency affected tumor
cell viability and proliferation.18 However, the absence of PD-L1
on MC38 and CT26 tumor cells did not hamper in vitro prolif-
eration (Fig. S1).
PD-L1 on cancer cells suppresses CD8C-mediated immune
control
In order to determine whether the lack of PD-L1 expression on
tumor cells alters tumor growth characteristics in vivo, we
injected immunocompetent mice with either WT or PD-L1KO
Figure 1. PD-L1 is expressed on tumor cells and infiltrating immune cells. (A) Immunohistochemistry for PD-L1 expression in MC38 (left) and CT26 (right) tumors. Cryosec-
tions of snap-frozen excised tumors were made 10 d after tumor inoculation and stained for PD-L1 expression (brown). Scale bars are provided in the bottom right corner.
Insert shows control staining with secondary antibody only. Representative images of n D 3 tumors. (B) Flow cytometry histograms showing PD-L1 expression of MC38
tumors cells (left plot) or CT26 tumor cells (right plot). WT tumor cells (black) or PD-L1KO tumor cells (red) were incubated for 48 h with IFNg and stained for PD-L1 expres-
sion (PE-conjugated antibody) for flow cytometry analysis, using isotype-PE stained cells (gray) as controls. (C) Flow cytometry histograms for PD-L1 expression (x-axis, PE-
conjugated antibody) of excised MC38 (left) or CT26 (right) tumors. Both tumors express PD-L1 on both tumor cells (solid black line) and on tumor-infiltrating immune
cells (dotted black line). (D) Flow cytometry histograms for PD-L1 expression of excised PD-L1KO MC38 (left) or CT26 (right) tumors showing lack of PD-L1 expression on
PD-L1KO tumor cells (solid red line) compared to infiltrating immune cells from PD-L1KO tumors retained high PD-L1 expression (dotted red line).
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tumor cells. Although both WT and PD-L1KO tumor cells formed
established tumors within one week after inoculation, subsequent
outgrowth of PD-L1KO MC38 tumors was significantly slower
compared to WT MC38 tumors (Fig. 2A). A similar delay in
tumor outgrowth was observed for PD-L1KO CT26 tumor cells
versus WT CT26 cells after injection in immunocompetent
BALB/c mice, albeit less pronounced than in the MC38 model
(Fig. 2B). Our observation of identical growth rates in culture but
delayed outgrowth of PD-L1KO cells in mice suggested that the
immune system inhibited growth of PD-L1KO tumors. To test
this, we treated mice-bearing PD-L1 proficient or deficient MC38
tumors with CD4C- or CD8C-depleting antibodies and followed
tumor outgrowth. Depletion of CD8C T cells or depletion of
both CD8C and CD4C T cells completely abrogated the delayed
outgrowth of PD-L1KO tumors, confirming our hypothesis on
the tumor-eradicating effector function of cytotoxic T cells in this
model (Fig. 2C). In contrast, depletion of only CD4C T cells
enhanced tumor clearance, suggesting that CD4C T cells in this
model most likely represent regulatory T cells, as has been pub-
lished in several settings (Fig. 2C).1,2 These findings of T cell-
dependent retardation of tumor outgrowth of PD-L1KO cancer
cells suggest active control by CD8C T cells, which are inhibited
by PD-L1 expressed on tumor cells.
Tumor microenvironment is not altered by PD-L1
deficiency of cancer cells
We observed high levels of PD-L1 expression on immune cells in
WT tumors, which may further contribute to the CD8C T cell-
mediated control of tumor outgrowth (Fig. 1B). It has recently
been published that tumor-infiltrating T cells can have a pro-
found effect on the myeloid composition of the tumor microenvi-
ronment.19,20 Therefore, we analyzed the immune infiltrate
composition in WT versus PD-L1KO tumors in the MC38 and
CT26 model. Surprisingly, no significant quantitative differences
in T cell infiltrate of WT versus PD-L1KO tumors were found
(Fig. 3A). Furthermore, neither total CD11bC myeloid infiltrate
was altered, nor were the Ly6CC and Ly6C¡ macrophages and
neutrophils. Moreover, PD-L1 expression levels on tumor-infil-
trating myeloid cells were not significantly altered by the lack of
PD-L1 expression on the malignant cells in either tumor model
(Fig. 3B). These results indicate that the composition of the mye-
loid immune infiltrate is not strongly influenced by PD-L1
expression on the malignant cells.
PD-L1 blockade is still effective against PD-L1KO tumors
To test whether the therapeutic efficacy of PD-L1 blockade is
solely based on alleviating immune suppression by PD-L1 expres-
sion on cancer cells, we examine treatment efficacy with PD-L1-
blocking antibody in mice carrying WT or PD-L1KO tumors.
Remarkably, outgrowth of PD-L1KO MC38 tumors was even fur-
ther decreased by therapeutic PD-L1 blockade, leading to com-
plete eradication of most tumors and long-term survival of nearly
90% of animals (Fig. 4A and Fig. S2 for individual tumor growth
curves). A less striking but similar additional effect of PD-L1
blockade in PD-L1KO tumors was found in the CT26 model
(Fig. 4B and Fig. S3 for individual tumor growth curves). These
data indicate that PD-L1 expression on non-tumor cells also con-
tribute to immune evasion and thereby tumor outgrowth. Deple-
tion of CD8C T cells during PD-L1 blockade of PD-L1KO MC38
tumors returned tumor growth rates to the level of untreated WT
tumors, showing that non-tumor cell expression of PD-L1 con-
tributes to the inhibition of effector CD8C T cell responses
(Fig. 4C). A similar effect was observed with therapy with a dif-
ferent PD-L1-blocking antibody clone (data not shown). To test
whether the absence of PD-L1 on cancer cells also influenced the
therapeutic efficacy of PD-1 blockade, we treated mice-bearing
WT or PD-L1KO MC38 tumors with PD-1-blocking antibody.
Again, there was an additional strong treatment effect by PD-1
Figure 2. PD-L1 on cancer cells suppresses CD8C T cell-mediated immune control. Tumor outgrowth curves of (A) MC38 and (B) CT26 tumors growing in B6 and BALB/c
mice, respectively. Mice were inoculated with either WT tumor cells (black circles) or PD-L1KO tumor cells (red squares) on day 0, and tumor volume was followed in time.
The graphs show the group average tumor volume and contain pooled data from three independent experiments with 20–22 mice (MC38) or two independent experi-
ments with 12–15 mice (CT26). Volumes of mice that had to be killed due to local ethical guidelines of maximal tolerated tumor size were afterwards counted as last mea-
sured volume. Line was stopped when more than 50% of mice in group had died due to tumor burden. By Student’s t test, differences in WT vs. PD-L1KO MC38 tumor
volumes are statistically significant on day 14 (p < 0.01) and days 17, 21 and 24 (p < 0.001). Differences in WT vs.PD-L1KO CT26 tumor volumes are statistically significant
on day 19 (p < 0.01). (C) Tumor outgrowth curves of PD-L1KO MC38 tumors either without treatment (solid black line), with CD4C-depleting antibody (solid red line,
closed squares), with CD8C-depleting antibody (dotted black line, open circles) or with both CD4C- and CD8C-depleting antibodies (dotted red line, open squares).
Tumors were inoculated on day 0, depleting antibodies were injected periodically from day 5 on, and tumor volume was followed in time. Volumes of mice that had to
be killed due to local ethical guidelines of maximal tolerated tumor size were afterwards counted as last measured volume. Line was stopped when more than 50% of
mice in group had died due to tumor burden. Differences in tumor volume compared to untreated PD-L1KO MC38 tumors are statistically significant (p < 0.05, Student’s
t test) for aCD4 treatment on days 13 through 25 (all p <0.01), for aCD8 treatment on days 13 (p < 0.05) and 15 (p < 0.01), and for aCD4C aCD8 treatment on days 11,
13 and 15 (all p < 0.001).
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blockade of PD-L1KO tumors, showing that the treatment effect
was effectively mediated through blocking the inhibiting PD-1/
PD-L1 interactions on non-tumor cells (Fig. 4D).
In parallel with a recently published study by Noguchi
et al.,21 our findings concur with the clinical study by Herbst
et al.,12 which describes that patients with PD-L1 expression on
tumor cells and/or immune infiltrate have a more favorable
outcome of therapeutic PD-L1 blockade. Our experimental
models provide a mechanistic basis underlying these clinical
observations, by showing that PD-L1 expression on both tumor
cells and on tumor-infiltrating immune cells inhibits CD8C T
cell responses against the tumor. Complete responses were
found in many, but not all animals. This can probably be
explained by the fact that PD-1/PD-L1 is only one of several
immune-inhibiting mechanisms. PD-1 also binds to PD-L2,
but its expression is less pronounced than PD-L1 expression.22
Several other compensatory interactions, such as upregulation
of LAG3, TIM-3 and other immune checkpoint molecules have
been found in tumors, indicating the diversity and flexibility of
the tumor–immune cell interactions.1 Therefore, combinatorial
therapies with immune-modulating antibodies, based on multi-
ple molecular interactions within the tumors, have more poten-
tial.1,2 Nonetheless, the great efficacy of PD-1/PD-L1 axis
blockade as monotherapy in curing mice from aggressive
tumors indicates a dominant role. Altogether, our work shows
that malignant cells and tumor-infiltrating immune cells jointly
suppress CD8C T cell responses by PD-L1 expression, and that
tumors lacking PD-L1 expression on malignant cells can be
efficiently treated by PD-1/PD-L1 axis blockade therapy.
Material and methods
Mice and cell lines
C57BL/6 mice were obtained from Harlan Laboratories–
ENVIGO (The Netherlands) and BALB/c mice were purchased
from Charles River (France) and housed under specified patho-
gen-free conditions in animal facilities of the Leiden University
Medical Center. All animal experimentations were approved by
and according to guidelines of the Dutch Animal Ethical com-
mittee. MC38 and CT26 cells (kindly provided by Mario
Colombo) were cultured in IMDM medium (Lonza) containing
8% Fetal Calf Serum (Greiner), 100 IU/mL penicillin/strepto-
mycin (Gibco), 2 mM glutamin (Gibco) and 25 mM 2-mercap-
toethanol. Cell lines were mycoplasma and MAP-tested before
the start of experiments.
Figure 3. Tumor microenvironment is not altered by PD-L1 deficiency of cancer cells. (A) Bar graphs showing the percentages of immune cell subsets infiltrating MC38
tumors (left) or CT26 tumors (right) comparing WT tumors (black bars) with PD-L1KO tumors (red bars). Established tumors were excised and processed for flow cytometry
analysis, using 7-AAD to exclude dead cells. Gating strategies are as follows; Total CD11b D CD45C CD11bC cells; Ly6CC MF D CD45C CD11bC F4-80C Ly6G¡ Ly6CC;
Ly6C¡ MF D CD45C CD11bC F4-80C Ly6G¡ Ly6C¡; Neutrophils D CD45C CD11bC Ly6GC and T cells: CD45C CD11b¡ CD3¡. None of the differences are statistically sig-
nificant. (B) Bar graphs showing the geometric mean fluorescence for PD-L1 expression (PE-conjugated antibody) on the myeloid immune subsets described in (A). None
of the differences are statistically significant according to the Student’s t test.
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Tumor inoculation and immunohistochemistry
Tumors were inoculated by subcutaneous injection in the right
flank of 500,000 MC38 cells or 100,000 CT26 cells in 100 mL
PBS. Tumor outgrowth was measured by caliper in three dimen-
sions, until mice had to be sacrificed due to tumor burden,
according to local ethical guidelines. For immunohistochemistry,
established tumors were excised on day 10 and 5 mm frozen sec-
tions were fixed using ice-cold acetone and blocked in 0.3%
hydrogen peroxidase (MERCK) in methanol. Next, slides were
stained for PD-L1 (clone 10F.9G2, BioLegend), secondary bio-
tin-conjugated rabbit anti-rat IgG (Boster Biological Technol-
ogy) and Vectastaincomplex (Vector labs). Color was developed
using DABC reagent (DAKO) and nuclei were counterstained
with Myers Haematoxylin (Merck). Slides were mounted using
Entellan (Merck). Photos were taken using an Olympus DX51
light microscope and Olympus cellSens software.
CRISPR/Cas9
For CRISPR/Cas9-knockout of PD-L1, an online CRISPR
Design Tool (crispr.mit.edu) was used to design two gRNA
sequences for exon 1 of the mouse cd274 gene encoding the
PD-L1 protein (gRNA #1 D GTATGGCAGCAACGTCACGA,
gRNA #2 D GCTTGCGTTAGTGGTGTACT) and each gRNA
was cloned into a gRNA cloning vector (Addgene 41824). Next,
MC38 or CT26 tumor cells were transfected with these two
gRNA plasmids (2 mg/plasmid) and with Cas9 WT (Addgene
41815), using the Lipofectamine 2000 protocol (Thermo-
Fisher). Cells were then stimulated for 48 h with 20 IU/mL
interferon-gamma to upregulate PD-L1 on WT cells and
stained with PE-labeled PD-L1 antibody for FACS-sorting of
PD-L1KO cells.
In vitro proliferation assay
3,000 cells of each tumor cell line were seeded, and after 24, 48
or 72 h cells were pulsed with 1 mM 3H and analyzed 15 h later.
Treatments
Tumor-bearing mice were treated on day 5, 8 and 11 after
tumor inoculation by intraperitoneal injection of 200 mg PD-
Figure 4. PD-L1 blockade is still effective against PD-L1KO tumors. Survival curves of mice bearing (A) MC38 or (B) CT26 tumors either left untreated (solid lines) or treated
with PD-L1 blocking antibody (dotted lines), comparing WT tumors (black lines) to PD-L1KO tumors (red lines). Antibodies were given on days 5, 8 and 11. For both tumor
models, tumor outgrowth curves of individual mice are provided in Figs. S2 and 3. In both tumor models, Log-rank analysis shows statistically significant differences (p <
0.05) between survival of each group compared to the others. (C) Survival curves of B6 mice bearing untreated WT MC38 tumors (solid black line), aPD-L1 treated PD-
L1KO MC38 tumors (dotted red line), or aPD-L1 treated PD-L1KO MC38 tumors with CD8C depletion (solid red line). The effect of CD8C depletion on the survival of aPD-
L1 treated PD-L1KO MC38 tumor-bearing mice is statistically significant (p < 0.05) using the Log-rank test. (D) Survival curves of B6 mice-bearing WT (black lines) or PD-
L1KO (red lines) MC38 tumors, either left untreated (solid lines) or treated with PD-1-blocking antibody on days 5, 8 and 11 (dotted lines). Log-rank analysis shows statisti-
cally significant (p < 0.05) differences in survival between untreated and PD-1-blockade-treated mice for both WT and PD-L1KO tumors. In all graphs, survival refers to
the time before reaching the maximally allowed tumor volume of 2,000 mm3.
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L1-blocking antibody (clone 10F.9G2, BioXCell) or peritumoral
subcutaneous injection of 50 mg PD-1-blocking antibody (clone
RMP1-14, BioXCell). T cells were depleted by intraperitoneal
injection of 50 mg depleting antibody (clone 2.43 for CD8C,
clone GK1.5 for CD4C, both in-house production) on day 5
after tumor inoculation. Complete depletion was confirmed on
the following day in peripheral blood by flow cytometry, and
mice were screened periodically and re-injected when T cell
populations started returning in peripheral blood.
Flow cytometry
Cell surface staining was performed using the following anti-
bodies: CD8a (clone 53–6.7), CD4C (clone L3T4), CD3e (clone
145-2c11), CD11b (clone M1/70), F4-80 (clone BM8), CD45.2
(clone 104), Ly6G (clone 1A8), Ly6C (clone HK1.4), PD-L1
(clone MIH5). For analysis of the tumor microenvironment,
tumor-bearing mice were sacrificed, and perfused with 20 mL
of PBS/EDTA (2 mM) to eliminate blood contamination of
tumor material. Tumors were cut into small pieces with scal-
pels, incubated with 2.5 mg/mL Liberase TL (Roche) for
20 min at 37C and single-cell suspensions were made using
70-mm cell strainers (BD Biosciences). Fc-receptors were
blocked with 10% normal mouse serum before antibody stain-
ing. Dead cells were excluded based on 7-AAD (Invitrogen).
Samples were analyzed with LSRII cytometer (BD) using Facs-
DIVA software (BD) and FlowJo software (Tree Star).
Statistical analysis
GraphPad Prism 7 software was used for all statistical analyses.
The means of two groups were compared using the Student’s t
test, and survival differences in Kaplan–Meier curves were ana-
lyzed by Log-rank test. Differences were considered statistically
significant at p <0.05.
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